Doktorlarımız

Halil Taşkaynatan

26.03.1984

EĞİTİM ve ÜNVANLAR:

2020: Tıbbi Onkoloji Doçenti

2018: Tıbbi Onkoloji Uzmanı

2017-2018: Emory Üniversitesi Winship Kanser Enstitüsü, Ürogenital Onkoloji, Observership Proğramı

2015-2018: İzmir Katip Çelebi Üniversitesi Atatürk Eğitim Araştırma Hastanesi, Tıbbi Onkoloji Uzmanlık Eğitimi

2014: İç hastalıkları Uzmanı

2009-2014: İzmir Katip Çelebi Üniversitesi Atatürk Eğitim Araştırma Hastanesi, İç Hastalıkları Uzmanlık Eğitimi

2003-2009: Eskişehir Osmangazi Üniversitesi Tıp Fakültesi,

1999-2002: Adana Fen Lisesi

1996-1999: Seyhan Anadolu Lisesi

ÖDÜL, SERTİFİKA ve ÜYELİKLER

2013-Türk Toraks Derneği

2015-Türk Tıbbi Onkoloji Derneği

2015-IZOG (Izmir Onkoloji Grubu)

2016-ESMO (Avrupa Tıbbi Onkoloji Derneği)

2015-2014 YDUS (Yan Dal Uzmanlık Sınavı) Birincilik Ödülü

2019– Tıbbi Onkoloji Yeterlik Belgesi

YABANCI DİL (YÖKDİL puanı:91)

HOBİLER: Piyano, Tenis

 

 

ULUSAL  YAYINLAR

1.      PrognosticValue of Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and Mean Platelet Volume (MPV) In Patients with Colorectal Carcinoma [Izmir Oncology Group(IZOG) Study]. Utku Oflazoğlu, Ahmet Alacacıoğlu, Işıl Somalı, Melike Yüce, Abdullah Murat Buyruk, Umut Varol, Tarık Salman, Halil Taşkaynatan, Yaşar Yıldız, Yüksel Küçükzeybek, İlhan Öztop,  Mustafa Oktay Tarhan. Acta Oncologica Turcica. Doi: 10.5505/aot.2017.09609.

2.      The Effect of Chemotherapy in Patients with Node-Negative pT1c Breast Cancer. Utku Oflazoğlu, Halil Taşkaynatan, Ümit Olcun Ünal, Umut Varol, Ahmet Alacacioğlu, Yüksel Kuçukzeybek, Tarik Salman, Yaşar Yildiz, Mustafa Oktay Tarhan. Acta Oncologica Turcica. Doi: 10.5505/aot.2018.77045.

 

3.      The Efficacy of Single Day Docetaxel, Cisplatin and 5- Fluorouracil Regimen in Patients With The Head and Neck Cancer. Halil Taşkaynatan, Altay İldan, Yaşar Yıldız, Utku Oflazoğlu, Ahmet Alacacıoğlu, Yüksel Küçükzeybek. Ege Klin Tıp Derg 2018; 56 (1): 17-22.

 

4.      The role of FOLFOXIRI in cehemorefractory metastatic colorectal cancer patients.Ibrahim Yildiz, Halil Taskaynatan, Umut Varol, Tarik Salman, Utku Oflazoglu, Yasar Yildiz, Yuksel Kucukzeybek, Ahmet Alacacioglu, Mustafa Oktay Tarhan. Journal of Oncological Sciences. 2018; 4(1):60-61.

5.      The Effect of Adjuvant Chemotherapy on Sexual Satisfaction and Quality of Life in Breast Cancer Patients and Their Partners Izmir Oncology Group (IZOG) Study. Utku Oflazoğlu, Umut Varol, Ahmet Alacacıoğlu, Nuri Aşık, Tarık Salman, Halil Taşkaynatan, Yüksel Küçükzeybek, Yaşar Yıldız, Mustafa Oktay Tarhan. Acta Oncologica Turcica. Doi: 10.5505/aot.2018.29494.

 

6. Evaluating Sexual Satisfaction and Quality of Life in Patients with Gynecological Cancer. Yaşar Yıldız, Ahmet Alacacıoğlu, Umut Varol, Yüksel Küçükzeybek, Nuri Aşık, Tarık Salman, Halil Taşkaynatan, Utku Oflazoglu, Murat Akyol, Mustafa Oktay Tarhan. Acta Oncologica Turcica. Doi: 10.5505/aot.2018.04834.

7. Prognostic Value of De-Ritis Ratio in Adolescents and Young Adult Patients with Breast Cancer. Utku Oflazoglu, Yakup iriagac, Yuksel Kucukzeybek, Umut Varol, Tarik Salman, Halil Taskaynatan, Yasar Yildiz, Ahmet Alacacioglu. Acta Oncologica Turcica. Doi: 10.5505/aot.2020.85619.

8. The Efficacy and Safety of Raltitrexed Therapy in Patients with Treatment Resistant Metastatic Colorectal Cancer. Yaşar Yıldız,Halil Taşkaynatan,Özlem Özdemir,Ahmet Alacacıoğlu,Utku Oflazoğlu,Yüksel Küçükzeybek. Ege Klin Tıp Derg 2019;57 (2): 86-90.

9. Evaluation of efficacy and toxicity of anthracycline plus cyclophosphamide every three weeks followed by weekly paclitaxel: The Izmır Oncology Group (IZOG) Study. Halil Taşkaynatan, Yılmaz Cankurtaran, Yüksel Küçükzeybek, Ahmet Alacacıoğlu, Yasar Yildiz, Tarık Salman, Utku Oflazoğlu, Umut Varol, Seray Sever, Mustafa Oktay Tarhan Acta Oncologica Turcica. Doi: 10.5505/aot.2019.05668.

10. Prognostic Significance of Immunohistochemical P53 Expression in Patients with Breast Cancer. Betül Bolat Küçükzeybek, Halil Taşkaynatan, Seyran Yiğit, Yaşar Yıldız, Ayşegül Akder Sarı, Utku Oflazoğlu, Demet Etit, Ayşe Yazıcı, Kemal Atahan, Ahmet Alacacıoğlu, Umut Varol, Yüksel Küçükzeybek. Acta Oncologica Turcica. Doi: 10.5505/aot.2018.55264.

 

 

ULUSLARARASI YAYINLAR

1. 
   Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S.Eur Urol Focus. 2020 Sep 30:S2405-4569(20)30269-8.

2. 
   Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study].

Varol U, Kaya E, Oflazoglu U, Salman T, Yildiz Y, Taskaynatan H, Saray S, Kucukzeybek Y, Alacacioglu A, Tarhan MO.J BUON. 2020 Mar-Apr;25(2):1063-1069.

3. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study].

Gurel Cayir E, Demir L, Varol U, Atahan MK, Salman T, Oflazoglu U, Yildiz Y, Taskaynatan H, Saray S, Kucukzeybek Y, Alacacioglu A, Tarhan MO.J BUON. 2020 Mar-Apr;25(2):675-680.

4. An analysis of adjuvant treatment strategies in operated pancreatic cancer patients: An Izmir oncology group study.

Varol U, Uzum Y, Sengul A, Korkmaz UB, Parvizi M, Akyol M, Taskaynatan H, Salman T, Oflazoglu U, Yildiz Y, Alacacioglu A, Kucukzeybek Y, Tarhan MO.Indian J Cancer. 2020 Apr-Jun;57(2):158-163.

5. 
   The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study).

Oflazoglu U, Alacacioglu A, Varol U, Kucukzeybek Y, Salman T, Onal HT, Yilmaz HE, Yildiz Y, Taskaynatan H, Saray S, Butun O, Tarhan MO.Support Care Cancer. 2020 Aug;28(8):3965-3977.

6. 
   The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast.

Dirilenoglu F, Etit DA, Taskaynatan H, Elmali F.Turk Patoloji Derg. 2020;36(3):195-204

7. Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor.

Salman T, Demir L, Varol U, Akyol M, Oflazoglu U, Yildiz Y, Taskaynatan H, Cengiz H, Guvendi G, Kucukzeybek Y, Alacacioglu A, Tarhan O.J BUON. 2016 Nov-Dec;21(6):1419-1424.

8. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.

Akyol M, Alacacioglu A, Demir L, Kucukzeybek Y, Yildiz Y, Gumus Z, Kara M, Salman T, Varol U, Taskaynatan H, Oflazoglu U, Bayoglu V, Tarhan MO.Cancer Biomark. 2017;18(4):441-449.

9. Is Monitoring Mean Platelet Volume Necessary in Breast Cancer Patients?

Taskaynatan H, Alacacioglu A, Kucukzeybek Y, Varol U, Yildiz Y, Salman T, Oflazoglu U, Tarhan MO.Open Med (Wars). 2018 Oct 4;13:450-455.

10. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.

Kucukzeybek BB, Bayoglu IV, Kucukzeybek Y, Yıldız Y, Oflazoglu U, Atahan MK, Taskaynatan H, Alacacioglu A, Yigit S, Tarhan MO.Pol J Pathol. 2018;69(2):157-168.

11. Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?

Taskaynatan H, Kucukzeybek Y, Alacacioglu A, Yildiz Y, Salman T, Oflazoglu U, Varol U, Bolat Kucukzeybek B, Kemal Atahan M, Oktay Tarhan M.J BUON. 2018 Jul-Aug;23(4):877-882.

12. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.

Yildiz Y, Kabadayi G, Yigit S, Kucukzeybek Y, Alacacioglu A, Varol U, Taskaynatan H, Salman T, Oflazoglu U, Akyol M, Tarhan MO.J BUON. 2019 Jul-Aug;24(4):1549-1554.

13. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study.

Oflazoglu U, Alacacioglu A, Varol U, Kucukzeybek Y, Salman T, Taskaynatan H, Yildiz Y, Saray S, Tarhan MO.Support Care Cancer. 2020 Jun;28(6):2899-2910.

14. 
    Prevalence and related factors of sarcopenia in newly diagnosed cancer patients.

Oflazoglu U, Alacacioglu A, Varol U, Kucukzeybek Y, Salman T, Taskaynatan H, Yildiz Y, Ozdemir O, Tarhan M.Support Care Cancer. 2020 Feb;28(2):837-843.

15. Serum levels of omentin-1 in patients with advanced epithelial ovarian cancer: the izmir oncology group (izog) study. Yildiz Y., Kucukzeybek Y., Alacacioglu A., Taskaynatan H., Yildiz İ. , Varol U., Demir L., Akyol M., Salman T., Oflazoglu U., Kalkan T., TARHAN M. O. Acta Medıca Medıterranea. 2017;33:549-555.

16. The Effects Of Adjuvant Chemotherapy On Serum Adma And Endothelın-1 Levels In Early Stage Breast Cancer Patıents ( Izmır Oncology Group (Izog) Study. Akyol M., Kara M., Alacacioglu A., Demir L., Ellidokuz H., Kucukzeybek Y., Yildiz Y., Bayoglu V., Yildiz İ. , Salman T., Varol U., Kucukzeybek B., Oflazoglu U., Taskaynatan H., Gumus Z., Tarhan M. O. Acta Medıca Medıterranea. 2017;33:557-564.

17. Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study. Halil Taskaynatan , Yuksel Kucukzeybek , Yasar Yildiz , Tarik Salman , Utku Oflazoglu , Umut Varol , Ahmet Alacacioglu , Seray Saray , Ozlem Ozdemir, Mustafa Oktay Tarhan. Annals of Medical Research. 2020;27(1):29-33.

18. Effect of diabetes mellitus on prognosis and development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Halil Taskaynatan , Gokmen Aktas , Sezgin Vatansever. Annals of Medical Research. 2019;26(10):2272-6.

19. Does Leukemoıd Reactıon Affect Prognosıs In Patıents Wıth Solıd Malıgnancıes? Halil Taskaynatan, Ummu Sena Sarı, Yasar Yildiz, Tarik Salman, Utku Oflazoglu, Umut Varol, Ozlem Ozdemir, Ahmet Alacacioglu, Tuna Demirdal, Fatih Esat Topal, Mustafa Oktay Tarhan, Yuksel Kucukzeybek. Acta Medıca Medıterranea. 2019, 35: 3437-3441.

20. The Relationship Between Thrombocyte Lymphocyte Ratio With Tumor Morphology and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma. Ümit Karaoğullarından, Hikmet Akkız, Sedef Kuran, Oğuz Üsküdar, Halil Taşkaynatan, Anıl Delik. TJFMPC, 2020;14(2): 230-235.

21.Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer. Y. Yildiz, Y. Kucukzeybek, A. Alacacioglu, U. Varol, I. Yildiz, M. Akyol, G. Kabadayı, H. Taskaynatan, T. Salman, V. Bayoglu, U. Oflazoglu, M.O. Tarhan. European Journal of Gynaecological Oncology.2017;38(3):444-448.

22. Ki-67 Labeling Index in Patients with EstrogenProgesterone Positive and Axillary Lymph Node Negative Breast Cancer. Betül Bolat Küçükzeybek, Halil Taşkaynatan, Ayşegül Akder Sarı, Seyran Yiğit, Gülden Ballı, Demet Etit, Ayşe Yazıcı, Murat Kemal Atahan, Dilara Özyiğit Büyüktalancı, Ahmet Alacacıoğlu, Yüksel Küçükzeybek. Konuralp Tıp Dergisi 2018;10(3): 387-394.

İLGİ ALANLARI

1. Meme kanseri

2. Genitoüriner Kanserler

3. Kolon Kanseri

4. Mide ve Pankreas Kanseri

5. Hepatobilier Kanserler

6. Akciğer Kanseri

7. Hedefe yönelik İlaçlar ve Bireyselleştirilmiş Tedavi

8. Kanser hastalarında egzersiz ve beslenme